It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Shiga toxin-producing Escherichia coli (STEC) cause diarrhea and dysentery, which may progress to hemolytic uremic syndrome (HUS). Vaccination has been proposed as a preventive approach against STEC infection; however, there is no vaccine for humans and those used in animals reduce but do not eliminate the intestinal colonization of STEC. The OmpT, Cah and Hes proteins are widely distributed among clinical STEC strains and are recognized by serum IgG and IgA in patients with HUS. Here, we develop a vaccine formulation based on two chimeric antigens containing epitopes of OmpT, Cah and Hes proteins against STEC strains. Intramuscular and intranasal immunization of mice with these chimeric antigens elicited systemic and local long-lasting humoral responses. However, the class of antibodies generated was dependent on the adjuvant and the route of administration. Moreover, while intramuscular immunization with the combination of the chimeric antigens conferred protection against colonization by STEC O157:H7, the intranasal conferred protection against renal damage caused by STEC O91:H21. This preclinical study supports the potential use of this formulation based on recombinant chimeric proteins as a preventive strategy against STEC infections.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Universidad de Chile, Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Santiago, Chile (GRID:grid.443909.3) (ISNI:0000 0004 0385 4466); Universidad de Chile, Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Santiago, Chile (GRID:grid.443909.3) (ISNI:0000 0004 0385 4466)
2 Universidad de Chile, Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Santiago, Chile (GRID:grid.443909.3) (ISNI:0000 0004 0385 4466)
3 Universidad de Talca, Centro de Bioinformática y Simulación Molecular, Facultad de Ingeniería, Talca, Chile (GRID:grid.10999.38)
4 Universidad de Concepción, Departamento de Microbiología, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663)
5 Universidad de Chile, Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Santiago, Chile (GRID:grid.443909.3) (ISNI:0000 0004 0385 4466); Universidad de Chile, Instituto Milenio de Inmunología e Inmunoterapia, Facultad de Medicina, Santiago, Chile (GRID:grid.443909.3) (ISNI:0000 0004 0385 4466)